CM Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

CM Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25,000	Closed	-$795K	–	99
2020 Q4	$795K	Buy	+25,000	New	+$657K	0.74%	48

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

CM Management's ITCI Position: Q1 2021 in Review

CM Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2021, closing a stake of 25,000 shares — an estimated $795K sold.

CM Management first reported a position in ITCI in Q4 2020 and held it in 1 quarter. The position peaked at $795K in Q4 2020. 170 funds tracked by Wall St. Rank hold ITCI as of Q1 2021.

CM Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2021 after selling out during the quarter.
CM Management sold 25,000 Intra-Cellular Therapies Inc. shares in Q1 2021, an estimated $795K.
CM Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 1 quarter.
CM Management's Intra-Cellular Therapies Inc. position peaked at $795K in Q4 2020.
170 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2021.

Based on CM Management's 13F filing for Q1 2021, filed 12 May 2021.